S 20478

Drug Profile

S 20478

Latest Information Update: 29 Aug 2006

Price : $50

At a glance

  • Originator ADIR
  • Developer Servier
  • Class Antihyperlipidaemics
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 29 Aug 2006 Discontinued - Preclinical for Atherosclerosis in France (unspecified route)
  • 10 Nov 1994 Preclinical development for Atherosclerosis in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top